Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab

Απλή σελίδα τεκμηρίου
dc.contributor.authorKoutras, A. K.en
dc.contributor.authorAntonacopoulou, A. G.en
dc.contributor.authorEleftheraki, A. G.en
dc.contributor.authorDimitrakopoulos, F. I.en
dc.contributor.authorKoumarianou, A.en
dc.contributor.authorVarthalitis, I.en
dc.contributor.authorFostira, F.en
dc.contributor.authorSgouros, J.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorBournakis, E.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorBompolaki, I.en
dc.contributor.authorGalani, E.en
dc.contributor.authorKalogeras, K. T.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorKalofonos, H. P.en
dc.date.accessioned2015-11-24T18:51:34Z
dc.date.available2015-11-24T18:51:34Z
dc.identifier.issn1473-1150-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18277
dc.rightsDefault Licence-
dc.titleVascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumaben
heal.abstractThe aim of the study was to evaluate the association of vascular endothelial growth factor (VEGF) genotypes with treatment efficacy in a randomized trial. This study compared two chemotherapy regimens (FOLFIRI versus XELIRI) combined with bevacizumab, as first-line treatment for metastatic colorectal cancer. DNA was extracted from blood samples of 173 patients participating in the trial. Genotyping was performed for selected SNPs (VEGF-1154, +936, -634, -2578 and -1498). All candidate genotypes were evaluated for associations with overall survival (OS), progression-free survival (PFS) and response rate (RR). There were no significant differences with respect to the distribution of genotypes in the treatment groups. The VEGF-1154 GG genotype was more frequent in patients not responding to treatment compared with responders (65.5 versus 39.8%, P=0.032). Furthermore, the VEGF-1154 GG genotype was associated with inferior median OS compared with GA (hazards ratio=1.68; 95% confidence interval: 1.10-2.57; P=0.016) or with the alternative genotypes (GA and AA) combined (hazards ratio=1.62; 95% confidence interval: 1.09-2.40; P=0.017). In multivariate analysis, the VEGF-1154 GG genotype remained a significant adverse factor for OS. Our results support the potential predictive ability of VEGF genotypes in patients with metastatic colorectal cancer receiving irinotecan-based chemotherapy plus bevacizumab, in terms of RR and OS. However, current results should be validated prospectively, in larger cohorts.The Pharmacogenomics Journal advance online publication, 16 August 2011; doi:10.1038/tpj.2011.37.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1038/tpj.2011.37-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/21844885-
heal.journalNamePharmacogenomics Jen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2011-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ